ストックスクリーナーアプリを入手
5.75
0.26%
-0.03
前日終値:
$5.78
開ける：
$5.85
24時間の取引高:
90,924
Relative Volume:
10.06
時価総額：
$36.42M
収益：
-
当期純損益:
$-14.72M
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
$-7.41M
1週間 パフォーマンス:
+1.59%
1か月 パフォーマンス:
+0.00%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$5.70
$5.85
1週間の範囲:
$5.35
$5.85
52週間の値動き範囲:
$5.35
$5.85
Alpha Cognition Inc Stock (ACOG) Company Profile
ACOG を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| ACOG | 5.74 | 36.42M | 0 | -14.72M | -7.41M | 0.00 |
| VRTX | 449.62 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 745.76 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 598.25 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.24 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.28 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Alpha Cognition Inc (ACOG) 最新ニュース
Alpha Cognition announces equity offering and warrant adjustments - Investing.com
Opening Day: Invizyne Technologies jumps after IPO - MSN
Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update - Business Wire
Alpha Cognition director Leonard Mertz acquires $49,996 in shares By Investing.com - Investing.com South Africa
Alpha cognition CEO Michael McFadden acquires shares worth $14,996 - Investing.com
Alpha cognition director John Havens buys $24,995 in common shares - Investing.com India
Alpha Cognition director Leonard Mertz acquires $49,996 in shares - Investing.com
Alpha Cognition Inc (ACOG-CN) QuotePress Release - The Globe and Mail
Alpha Cognition Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Alpha Cognition Inc (ACOGF) Quarterly 10-Q Report - Quartzy
Canada market stock losers: Tidewater Renewables Ltd. looses 12.43% while Rektron Group Inc dips by 10.33% during mid day trading - Business Upturn
Alpha Cognition Announces Pricing of $50 Million Upsized Public Offering and Nasdaq Listing - Business Wire
Canada Market Top Losers: AYR Wellness down 47.30%, Trulieve Cannabis falls 40%, - Business Upturn
Alpha Cognition Inc. announced that it has received $4.545 million in funding - Marketscreener.com
Alpha Cognition Plans Nasdaq Listing and $25M Offering - TipRanks
Xavier Creative House Hires Jami Rogers as Vice President of Sales & Marketing - citybiz
Alpha Cognition Announces Appointment of VP Finance and Accounting - Business Wire
Alpha Cognition Inc (ACOGF) QuotePress Release - The Globe and Mail
Alpha Cognition Announces Executive Shake-up & Drug Approval - TipRanks
Alpha Cognition Announces Change of Officer - Business Wire
Spartan Capital Securities Serves as Selling Group Member - GlobeNewswire
Alpha Cognition Announces Completion of $4.545 Million (USD) Convertible Note and Warrants Bridge Financing - BioSpace
Alpha Cognition sets annual meeting for September 27 - Investing.com
July FDA approvals target Alzheimer's, myeloma and wet AMD - BioWorld Online
Alpha Cognition Receives Notice of Allowance for Composition-of-Matter Patent for ZUNVEYL® for Mild to Moderate Alzheimer’s Disease - Yahoo Finance
Alpha Cognition Inc. Adjusts Funding Strategy Amid Market Challenges - TipRanks
FDA approves AChEI ALPHA-1062 for Alzheimer’s disease treatment - News-Medical.Net
Cognition Therapeutics: Shines Less Bright After Phase 2 Results In Alzheimer's Disease - Seeking Alpha
FDA favors Zunveyl, Alzheimer's therapy showing better tolerability - Alzheimer's News Today
FDA approves Alpha Cognition's Zunveyl to treat Alzheimer's disease | 2024-07-29 | Investing News - Stockhouse Publishing
Breakeven On The Horizon For Alpha Cognition Inc. (CSE:ACOG) - Simply Wall St
Alpha Cognition upgraded at Raymond James - Cantech Letter
Early Inflammation Linked to Midlife Cognitive Decline - Neuroscience News
What’s Coming Down the Pike: Drug Approvals in the Second Half of ’24 - Managed Healthcare Executive
Alpha Cognition Announces First Quarter of 2024 Results and Provides Corporate Update - Business Wire
Cognition Therapeutics: Approaching Phase 2 Readout In Alzheimer’s (NASDAQ:CGTX) - Seeking Alpha
Alpha Cognition Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update - Yahoo Finance
Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now - GlobeNewswire
Alpha Cognition Files U.S. Patent Application Covering an ALPHA-1062 Oral Formulation to Treat Mild to Moderate Alzheimer’s Disease - Yahoo Finance
Alpha Cognition Provides Business Update - Business Wire
Alpha Cognition Announces Fourth Closing of Private Placement and Continuation of the Offering - Yahoo Finance
Alpha Cognition Announces FDA Acceptance of New Drug Application for ALPHA-1062 for Mild-to-Moderate Alzheimer’s Disease - Business Wire
BioNTX iC3 Summit to Fuel North Texas Life Science Ecosystem, Honor 8 Rising Stars - dallasinnovates.com
Alpha Cognition gets rating downgrade from Raymond James - Cantech Letter
Relmada Therapeutics Appoints CNS Therapeutic Expert Cedric O'Gorman MD as Chief Medical Officer - PR Newswire
Data: ALPHA-1062 a Bioequivalent to Approved Therapy Razadyne - Alzheimer's News Today
Progranulin Gene Therapy Shows Promise in Preclinical Studies - ALS News Today
Alpha Cognition could have a best-in-class Alzheimer’s drug, iA Capital says - Cantech Letter
Pharmaceutical Entrepreneur Fred Sancilio Speaks on His Vast Industry Experience - Thrive Global
Alpha Cognition Inc (ACOG) 財務データ
収益
当期純利益
現金流量
EPS
Alpha Cognition Inc (ACOG) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| MERTZ LEONARD POWELL | Director |
Nov 13 '24 |
Buy |
5.75 |
8,695 |
49,996 |
93,725 |
| HAVENS JOHN PRENTISS | Director |
Nov 13 '24 |
Buy |
5.75 |
4,347 |
24,995 |
273,272 |
1.80%
0.42%
大文字化:
|
ボリューム (24 時間):